<DOC>
	<DOCNO>NCT01622088</DOCNO>
	<brief_summary>The purpose study collect long-term safety data subject Amyotrophic Lateral Sclerosis ( ALS ) expose dexpramipexole .</brief_summary>
	<brief_title>Phase 3 Extension Study Dexpramipexole ALS</brief_title>
	<detailed_description>Amyotrophic Lateral Sclerosis ( ALS ) rapidly progressive , degenerative disease motor neuron brain spinal cord lead muscle atrophy spasticity limb bulbar muscle result weakness loss ambulation , oropharyngeal dysfunction , weight loss , ultimately respiratory failure . The purpose study collect long-term safety data subject Amyotrophic Lateral Sclerosis ( ALS ) expose dexpramipexole .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Subject ability understand purpose risk study provide sign date informed consent ( consent confirm witness unable write ) authorization use protect health information ( PHI ) accordance national local subject privacy regulation . Subject enrol either CL211 ( NCT00931944 ) Study 223AS302 ( NCTO1281189 ) . Subject complete last visit Study CL211 ( NCT00931944 ) Study 223AS302 ( NCTO1281189 ) . Subjects childbearing potential must practice effective contraception study willing able continue contraception 1 month ( female ) 3 month ( male ) last dose study treatment . Subject withdraw prematurely Study CL211 ( NCT00931944 ) Study 223AS302 ( NCTO1281189 ) . Subject permanently discontinue study treatment Study CL211 ( NCT00931944 ) Study 223AS302 ( NCTO1281189 ) reason enrollment study . Subject Study CL211 ( NCT00931944 ) Study 223AS302 ( NCTO1281189 ) significant change medical history ( include laboratory test clinically significant condition ) opinion Investigator would impair subject 's medical fitness participation preclude treatment . Female subject pregnant breastfeeding . Subject currently enrol investigational drug study Study CL211 ( NCT00931944 ) Study 223AS302 ( NCTO1281189 ) . Subject take pramipexole , dopamine agonist , agent dopaminergic activity , disallow concomitant medication . Subject unwilling unable comply requirement protocol include presence condition ( physical , mental , social ) likely affect subject 's ability comply protocol . At minimum , subject able travel study site must willing agree remote blood draw clinical laboratory evaluation telephone visit report Adverse Events , concomitant medication , Amyotrophic Lateral Sclerosis Functional Rating Scale ( revise ) ( ALSFRSR ) score .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>ALS , Motor Neuron Disease , Amyotrophic Lateral Sclerosis</keyword>
</DOC>